Magenta Medical
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
$4.0m | Seed | ||
* | $15.0m | Series B | |
* | $10.0m | Late VC | |
* | $55.0m | Late VC | |
* | $105m | Late VC | |
Total Funding | $189m |
Recent News about Magenta Medical
EditMagenta Medical develops advanced medical devices focused on providing temporary support for patients with severe heart conditions. The company specializes in two main products: the percutaneous Left Ventricular Assist Device (pLVAD) and the Transcatheter Renal Venous Decongestion System. The pLVAD is a next-generation, low-profile arterial pump designed to offer temporary support for patients undergoing high-risk coronary interventions and those suffering from cardiogenic shock. The Transcatheter Renal Venous Decongestion System is a venous pump aimed at treating hospitalized patients with acutely decompensated heart failure by reducing renal venous pressure and decompressing the kidneys.
Magenta Medical primarily serves hospitals and healthcare providers dealing with critical heart failure cases. Operating in the medical device market, the company employs a business model that includes the development, manufacturing, and sale of its specialized pumps. Revenue is generated through direct sales to healthcare institutions and partnerships with medical distributors.
Keywords: heart failure, pLVAD, arterial pump, venous pump, coronary interventions, cardiogenic shock, renal venous pressure, decompensated heart failure, medical devices, healthcare providers.